PDxMolecular-Imaging-Herov2

Nuclear Imaging Agents

A rendering error occurred: Loading CSS chunk 225 failed. (/dist/GEHC/Project/GEHC/static/css/LinkListingModule.aa8f104a.chunk.css).

Because together we can shape the future

Our Mission
Bringing clinically relevant applications to areas of high unmet needs, improving both access and outcomes for patients. We are working to increase the value of Molecular Imaging (MI) for patient management, by delivering products, solutions, services and expertise to healthcare providers and for therapy innovators around the world.

Our Vision
Embracing a culture of partnership to transform the future of Molecular Imaging. We are collaborating with our customers and partners in the pursuit of precision health.

A rendering error occurred: Loading CSS chunk 225 failed. (/dist/GEHC/Project/GEHC/static/css/LinkListingModule.aa8f104a.chunk.css).

Providing a broad portfolio

Molecular Imaging in Precision Health

Building Expertise

Pioneering Research

Molecular Imaging Insights

Providing a Broad
Portfolio

You can count on a broad portfolio of products and solutions

Uncompromised quality & reliability in everything we do: 30+ products covering main care areas. Significant evidence base for product use, integrated in key international guidelines, all our production sites are cGMP accredited. Fully compliant with regulations and legislation from Health Authorities worldwide.
Mi2

  • Cardiology

  • Cell labelling-Infection

  • Kidney Function

  • Liver-Gall Bladder

  • Lung Perfusion

  • Neurology

  • Oncology

  • Thyroid

Products

Prescribing Information

Please click here for DaTSCAN prescribing information.

Please click here for SeHCAT prescribing information.

Please click here for Rapiscan prescribing information.

 

Adverse events should be reported
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk
Adverse events should also be reported to GE Healthcare at gpv.drugsafety@gehealthcare.com

Molecular Imaging
in Precision Health

We continue to put the future first, globally

By bringing clinically relevant applications to the market, improving access to nuclear medicine and enhancing outcomes for patients.

Building Expertise

Pioneering Research

Significant R&D investment. Enhancing diagnostic accuracy to enable you to improve patient outcomes

  • $25M

    R&D investment in 2018

     

  • 16

    innovative products launched in 15 years

  • 198

    patent applications in 10 years

Enhancing clinical trials. New diagnostic options for clinicians and their patients

  • 35

    GE sponsored clinical trials

  • 69

    external clinical studies

     

  • Continued focus on development of new tracers

Strong pharma partnership. Advance in companion diagnostics for personalised treatment

  • 4200+

    doses delivered for clinical trials in 2018 worldwide

  • 15+

    contracts over the last 5 years to study innovative drugs

Contact Us

The form cannot be displayed because of the privacy settings of your browser. Please modify your privacy settings and retry.

DaTSCAN, Rapiscan and SeHCAT are trademarks of GE.
JB01438UK | August 2021

JB01438UK